BioSpace News Archive

Policy

Novo Nordisk Files Another Round of Lawsuits Over Semaglutide Copycats

After an initial series of legal complaints in June, Novo Nordisk filed four new lawsuits Thursday against Florida and Tennessee pharmacies for allegedly selling products containing semaglutide.

July 7, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Roche’s Tecentriq Boosts Survival in NSCLC Patients Ineligible for Platinum Chemo

Phase III trial data published Thursday show significant survival benefit as a first-line treatment in advanced non-small cell lung cancer patients not fit for standard platinum-based doublet chemotherapy.

July 7, 2023
·
2 min read
·
Tristan Manalac
Policy

CMS Expands Medicare Coverage for Leqembi After FDA Traditional Approval

Following the FDA’s full approval of the Alzheimer’s drug Thursday, the Centers for Medicare and Medicaid Services confirmed broader coverage of Leqembi and released more details on a registry.

July 7, 2023
·
2 min read
·
Tristan Manalac
Drug Development

CRISPR on the Cusp: The Promise and the Pain Points

Gene editing technologies are advancing rapidly in the clinic, with the potential first approval later this year, but challenges remain.

July 7, 2023
·
7 min read
·
Natalia Mesa
Business

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results - July 07, 2023

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, provided an operational update and released financial results for the fiscal year ended April 30, 2023.

July 7, 2023
·
10 min read
Drug Development

BrainStorm Cell Therapeutics Data Show Treatment with NurOwn Significantly Reduces NfL, a Key Biomarker of Neurodegeneration

BrainStorm Cell Therapeutics Inc. this week presented new biomarker data from the Phase 3 trial of its late-stage investigational ALS treatment, NurOwn at the 2023 ALS and Related Motor Neuron Diseases Gordon Research Conference.

July 7, 2023
·
10 min read
Genetown

BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023

BeiGene today announced that the Company will host an investor Research and Development Day in New York City and via webcast on July 18, 2023.

July 7, 2023
·
2 min read
Drug Development

European Patent Granted for ZyVersa Therapeutics’ Lead Asset, Cholesterol Efflux Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease

ZyVersa Therapeutics, Inc. announces that the European Patent Office granted a patent covering the company’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 (2-hydroxypropyl-beta-cyclodextrin) for use in diabetic nephropathy/diabetic kidney disease (Patent Number EP 2 836 221).

July 7, 2023
·
5 min read
Deals

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 7, 2023

Insmed Incorporated today announced the granting of inducement awards to 10 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed’s Compensation Committee and made as a material inducement to each employee’s entry into employment with the Company.

July 7, 2023
·
1 min read
FDA

ICHNOS SCIENCES RECEIVES ORPHAN DRUG DESIGNATION FOR FIRST-IN-CLASS TRISPECIFIC ANTIBODY, ISB 2001

Ichnos Sciences Inc. today announced it has been granted orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA) for its first-in-class T-cell engaging trispecific antibody, ISB 2001, for the treatment of multiple myeloma.

July 7, 2023
·
4 min read